Mission

Our objectives are:

To combine data from multiple cohorts in order to identify VEGF ‘-omics’ profiling in health and non-communicable diseases
To elucidate the pivotal role of VEGF in the pathophysiology of non-communicable diseases
To demonstrate the patients’ stratification potential of VEGF ‘-omics’ profiling
To implement the research results into clinical practice and establish the role of VEGF as a predictive, preventive, diagnostic and prognostic biomarker
To provide information on the effect of VEGF ‘-omics’ profiling in side effects and response to therapy through pharmacogenomics studies
To propose implementation strategies and European guidelines involving VEGF ‘-omics’ profiling for the management of non-communicable diseases
To share methodologies, data and knowledge in the field of ‘-omics’ management and innovative statistics
To develop standardized teaching and evaluation methods practiced and validated by the Consortium

Our objectives are:

To combine data from multiple cohorts in order to identify VEGF ‘-omics’ profiling in health and non-communicable diseases
To elucidate the pivotal role of VEGF in the pathophysiology of non-communicable diseases
To demonstrate the patients’ stratification potential of VEGF ‘-omics’ profiling
To implement the research results into clinical practice and establish the role of VEGF as a predictive, preventive, diagnostic and prognostic biomarker
To provide information on the effect of VEGF ‘-omics’ profiling in side effects and response to therapy through pharmacogenomics studies
To propose implementation strategies and European guidelines involving VEGF ‘-omics’ profiling for the management of non-communicable diseases
To share methodologies, data and knowledge in the field of ‘-omics’ management and innovative statistics

To develop standardized teaching and evaluation methods practiced and validated by the Consortium